GlycoVaxyn
Company developing a broad portfolio of bioconjugate vaccines to PREvent common bacterial infections using its proprietary glycoprotein technology
GlycoVaxyn has raised €17M across 2 funding rounds from 3 investors, most recently a Series B round in Mar 2009. Based in Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€17M
€17,475,212
Funding rounds
2
Investors
3
distinct backers
Active since
2006-07
latest 2009-03
Funding by year
EUR raised per yearGlycoVaxyn — funding by year — interactive chart.
Data table
| GlycoVaxyn — funding by year | |
|---|---|
| 2006 | €629k |
| 2009 | €17M |
Signals
High confidenceRaise-next likelihood11
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
Exit likelihood5
base rate 11% (2+ rounds)
- ▼ Old (20y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2009-03-01 | Series B | €17M | Edmond de Rothschild Venture Capital,Index Ventures,Sofinnova Partners | View deal → |
| 2006-07-01 | Series A | €629k | Index Ventures,Sofinnova Partners | View deal → |
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData